A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Natarajan, Rama, Ph.D, F.A.H.A, F.A.S.N. Research Bookmark and Share

Rama Natarajan, Ph.D, F.A.H.A, F.A.S.N. Research

The major focus of our research is to determine the cellular and molecular mechanisms that play key roles in the development of diabetic vascular complications. We use genomic, transcriptomic and epigenomic approaches in cell culture, animal and clinical models to examine our hypothesis that accelerated vascular complications result from enhanced vascular and renal cell growth, and also monocyte activation due to altered expression of inflammatory cytokines, chemokines and lipids under diabetic conditions.
 
We are actively evaluating molecular mechanisms involved in the expression of pathological genes under diabetic conditions and in promoting metabolic memory. We have demonstrated the role of specific chromatin histone posttranslational modifications in the epigenetic regulation of inflammatory genes. We use epigenomic profiling approaches to map histone modifications, DNA methylation and binding of chromatin factors at diabetes-regulated genes with techniques such as Chromatin immunoprecipitation (ChIP) assays, ChIP-linked to microarrays, and ChIP-Sequencing. We have uncovered key epigenetic alterations under diabetic conditions in vitro, in vivo in diabetic mice, and in cells from diabetic patients, and shown relevance to the phenomenon of metabolic memory.
 
Another active area is the evaluation of specific microRNAs in regulating the expression of inflammatory and fibrotic genes under diabetic conditions. We are examining various mechanisms of microRNA regulation, performing expression profiling using RNA-sequencing, and studying how key microRNAs co-operate with each other in a circuit to amplify the effects of growth factors under diabetic conditions. To test the functional significance in the kidney, we are generating microRNA knockout mice and also evaluating novel modified inhibitors of specific microRNAs (antagomirs) on the progression of diabetic kidney disease in mouse models.
 

Rama Natarajan, Ph.D., Lab Members

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rama Natarajan, Ph.D., F.A.H.A, F.A.S.N.
National Office Products Endowed Professor
626-256-HOPE (4673), ext. 62289
 
Marpadga A. Reddy, Ph.D.
Assistant Research Professor
626-256-HOPE (4673), ext. 63671
 
Feng Miao, Ph.D.
Assistant Research Professor
626-256-HOPE (4673), ext. 65575
 
Mitsuo Kato, Ph.D.
Assistant Research Professor
626-256-HOPE (4673), ext. 63996
 
Kirti Bhatt, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 65811
 
Nancy Castro, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 64690
 
Ye Jia, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 62289
 
Amy Leung, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 62278
 
Jung-tak Park, M.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 64809
 
Hang Yuan, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 65817
 
Supriya Deschpande
Graduate Student
626-256-HOPE (4673), ext. 65835
 
Wen Jin
Graduate Student
626-256-HOPE (4673), ext. 65823
 
Linda Lanting, B.S.
Research Associate
626-256-HOPE (4673), ext. 64692
 
Mei Wang, M.S.
Research Associate
626-256-HOPE (4673), ext. 64676
 
Lingxiao Zhang, M.S.
Research Associate
626-256-HOPE (4673), ext. 65571
 
Nancy (Zhuo) Chen
Bioinformatics Specialist
656-256-HOPE (4673), ext. 65058
 

Natarajan, Rama, Ph.D, F.A.H.A, F.A.S.N. Research

Rama Natarajan, Ph.D, F.A.H.A, F.A.S.N. Research

The major focus of our research is to determine the cellular and molecular mechanisms that play key roles in the development of diabetic vascular complications. We use genomic, transcriptomic and epigenomic approaches in cell culture, animal and clinical models to examine our hypothesis that accelerated vascular complications result from enhanced vascular and renal cell growth, and also monocyte activation due to altered expression of inflammatory cytokines, chemokines and lipids under diabetic conditions.
 
We are actively evaluating molecular mechanisms involved in the expression of pathological genes under diabetic conditions and in promoting metabolic memory. We have demonstrated the role of specific chromatin histone posttranslational modifications in the epigenetic regulation of inflammatory genes. We use epigenomic profiling approaches to map histone modifications, DNA methylation and binding of chromatin factors at diabetes-regulated genes with techniques such as Chromatin immunoprecipitation (ChIP) assays, ChIP-linked to microarrays, and ChIP-Sequencing. We have uncovered key epigenetic alterations under diabetic conditions in vitro, in vivo in diabetic mice, and in cells from diabetic patients, and shown relevance to the phenomenon of metabolic memory.
 
Another active area is the evaluation of specific microRNAs in regulating the expression of inflammatory and fibrotic genes under diabetic conditions. We are examining various mechanisms of microRNA regulation, performing expression profiling using RNA-sequencing, and studying how key microRNAs co-operate with each other in a circuit to amplify the effects of growth factors under diabetic conditions. To test the functional significance in the kidney, we are generating microRNA knockout mice and also evaluating novel modified inhibitors of specific microRNAs (antagomirs) on the progression of diabetic kidney disease in mouse models.
 

Lab Members

Rama Natarajan, Ph.D., Lab Members

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rama Natarajan, Ph.D., F.A.H.A, F.A.S.N.
National Office Products Endowed Professor
626-256-HOPE (4673), ext. 62289
 
Marpadga A. Reddy, Ph.D.
Assistant Research Professor
626-256-HOPE (4673), ext. 63671
 
Feng Miao, Ph.D.
Assistant Research Professor
626-256-HOPE (4673), ext. 65575
 
Mitsuo Kato, Ph.D.
Assistant Research Professor
626-256-HOPE (4673), ext. 63996
 
Kirti Bhatt, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 65811
 
Nancy Castro, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 64690
 
Ye Jia, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 62289
 
Amy Leung, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 62278
 
Jung-tak Park, M.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 64809
 
Hang Yuan, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 65817
 
Supriya Deschpande
Graduate Student
626-256-HOPE (4673), ext. 65835
 
Wen Jin
Graduate Student
626-256-HOPE (4673), ext. 65823
 
Linda Lanting, B.S.
Research Associate
626-256-HOPE (4673), ext. 64692
 
Mei Wang, M.S.
Research Associate
626-256-HOPE (4673), ext. 64676
 
Lingxiao Zhang, M.S.
Research Associate
626-256-HOPE (4673), ext. 65571
 
Nancy (Zhuo) Chen
Bioinformatics Specialist
656-256-HOPE (4673), ext. 65058
 
Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.

Learn more about
City of Hope's institutional distinctions, breakthrough innovations and collaborations.
 
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 


NEWS & UPDATES
  • It was 2009 when a City of Hope patient in her 40s learned that the cancer she had been fighting for several years had metastasized to her lungs. Her medical team ran genetic tests on the tumor, but none of the drug therapies available at the time targeted the known mutations in the tumor cells. […]
  • Acute myeloid leukemia (AML) is characterized by a rapidly-developing cancer in the myeloid line of blood cells, which is responsible for producing red blood cells, platelets and several types of white blood cells called granulocytes. Because AML grows rapidly, it can quickly crowd out normal blood cells, leadi...
  • Rachel Divine is a yoga therapist and patient leader for the Sheri & Les Biller Patient and Family Resource Center. She’s also a former City of Hope patient. When someone you know has cancer, even the word “cancer” can make you feel nervous, sleepless, depressed or more. But, as a yoga teacher for 15 ...
  •   Diagnosed with type 1 diabetes when she was 9 years old, Gina Marchini accepted the fact that she would need insulin the rest of her life. Every day, she injected herself with the lifesaving hormone. She also carefully controlled her diet and monitored the rise and fall of her blood glucose with military...
  • The defeat of cancer will require a team effort. Nowhere is this more necessary (or apparent) than in efforts to combat two of the most deadly forms of the disease  – pancreatic cancer and triple-negative breast cancer. It’s the approach City of Hope is taking with its newly launched multidisciplinary teams, br...
  • It’s a reasonable question: Why is the National Cancer Institute funding a study on preventing heart failure? The answer is reasonable as well: Rates of heart failure are drastically high among childhood cancer survivors — 15 times higher than among people the same age who were never treated for cancer. T...
  • Many teenagers take a break from academics during the summer, but not the eight high school students enrolled in the California Institute for Regenerative Medicine (CIRM) Creativity Awards program at City of Hope. They took the opportunity to obtain as much hands-on research experience as possible, learning fro...
  • About one in eight women will develop breast cancer at some point in her life. In fact, breast cancer is the most common cancer in American women, behind skin cancer. Although women can’t change some risk factors, such as genetics and the natural aging process, there are certain things they can do to lower thei...
  • As genetic testing becomes more sophisticated, doctors and their patients are finding that such tests can lead to the discovery of previously unknown cancer risks. In his practice at City of Hope, Thomas Slavin, M.D., an assistant clinical professor in the Division of Clinical Cancer Genetics, sees the full spe...
  • And the winners are … everyone in the San Gabriel Valley. The recipients of City of Hope’s first-ever Healthy Living grants have been announced, and the future is looking healthier already. In selecting San Gabriel Valley organizations to receive the grants, City of Hope’s Community Benefits Advisory Council ch...
  • Barry Leshowitz is a former City of Hope patient and a family advisor for the Sheri & Les Biller Patient and Family Resource Center. It’s been almost seven years since I checked into a local hospital in Phoenix for a hip replacement, only to be informed by the surgeon that he had canceled the surgery....
  • When it comes to science, the best graduate schools don’t just train scientists, they prepare their students for a lifetime of learning, accomplishment and positive impact on society. At City of Hope, the Irell & Manella Graduate School of Biological Sciences goes one step further – by preparing students to...
  • Cancer affects not just the cancer patient, but everyone around him or her, even after treatment is complete. The challenges can include the fear of cancer recurrence, coping with cancer’s economic impact and the struggle to achieve work-life balance post-treatment. Family members and loved ones of cancer patie...
  •   Bladder cancer facts: Bladder cancer is a disease in which malignant (cancer) cells form in the tissues of the bladder. 2015 estimates: 74,000 new cases of bladder cancer diagnosed 16,000 deaths from bladder cancer (about 11,510 in men and 4,490 in women) Risk factors for bladder cancer: Smoking: Smokers...
  • Women with ovarian cancer have questions about the most promising treatment options, revolutionary research avenues, survivorship and, of course, the potential impact on their personal lives. Now, together in one place, are experts who can provide answers. On Saturday, Sept. 12, the 2015 Ovarian Cancer Survivor...